Gpc4 Antibody

What is GPC4 and why is it important in biological research?

GPC4 (Glypican 4) is a member of the glypican family of glycosylphosphatidylinositol (GPI)-anchored heparan sulfate proteoglycans (HSPGs) that plays significant roles in cell division and growth regulation . As a cell surface proteoglycan, GPC4 participates in crucial developmental processes, particularly in kidney tubule formation and central nervous system development .

The importance of GPC4 in research stems from its involvement in multiple signaling pathways and its interactions with various growth factors and signaling molecules that influence cell proliferation, migration, and differentiation . Dysregulation of GPC4 expression has been implicated in several pathological conditions, including cancer, cardiovascular disorders, and developmental abnormalities . These diverse biological functions make GPC4 an important target for researchers studying developmental biology, cancer, and various disease mechanisms.

Glypicans, including GPC4, are highly conserved proteoglycans crucial for regulating cell signaling during development, with six family members (GPC1 to GPC6) identified in mammals . Their study provides insights into fundamental biological processes and potential therapeutic targets for various diseases.

What are the main types of GPC4 antibodies available for research?

Several types of GPC4 antibodies are available for research applications, each with distinct characteristics:

• Polyclonal GPC4 antibodies: These are the most commonly available type, such as:

  • Rabbit polyclonal antibodies (e.g., 13048-1-AP from Proteintech, ab246973 from Abcam, TA316798 from OriGene, and CAB12805 from Assay Genie)

  • These antibodies typically recognize multiple epitopes on the GPC4 protein

• Recombinant antibodies: More recently developed, these offer enhanced reproducibility:

  • Chimeric recombinant antibodies with fused human variable and rabbit constant domains (offered by the Institute for Protein Innovation)

  • These antibodies undergo extensive characterization, including mass spectrometry, size exclusion chromatography, surface plasmon resonance, and cross-reactivity analysis

The choice between antibody types depends on the specific research application, with each offering distinct advantages. Polyclonal antibodies often provide higher sensitivity due to recognition of multiple epitopes, while recombinant antibodies offer greater batch-to-batch consistency and defined specificity profiles .

What applications are GPC4 antibodies validated for?

GPC4 antibodies are validated for multiple research applications, with different antibodies showing utility across various techniques:

It's recommended that researchers titrate these antibodies in their specific testing systems to obtain optimal results, as performance can be sample-dependent . For immunohistochemistry applications with paraffin-embedded tissues, antigen retrieval with TE buffer pH 9.0 or alternatively with citrate buffer pH 6.0 is suggested for optimal staining .

How should I select the appropriate GPC4 antibody for my specific research application?

Selecting the appropriate GPC4 antibody requires consideration of several key factors:

• Species compatibility: Verify that the antibody reacts with your species of interest. For example:

  • 13048-1-AP shows reactivity with human, mouse, and rat samples

  • ab246973 is validated for human samples

  • TA316798 shows reactivity with human and gorilla, with predicted reactivity in monkey and rabbit

  • CAB12805 reacts with human and mouse samples

• Application suitability: Confirm the antibody is validated for your intended application:

  • For Western blot, 13048-1-AP has been extensively validated across 13 publications

  • For immunohistochemistry on paraffin sections, ab246973, TA316798, and 13048-1-AP are validated options

  • For flow cytometry, recombinant antibodies from IPI are specifically validated

• Epitope considerations: Consider which region of GPC4 you need to target:

  • TA316798 is raised against a synthetic 16 amino acid peptide from the C-terminus of human GPC4

  • ab246973 targets a recombinant fragment within human GPC4 amino acids 450-550

• Validation data: Review available validation data, including published literature references and manufacturer-provided data such as images, specific tissues/cells where positive signals were detected, and cross-reactivity information. Some antibodies (13048-1-AP) have been cited in multiple publications, providing additional confidence in their performance .

For critical research applications, consider testing multiple antibodies in parallel to confirm results, especially when exploring GPC4 expression in novel contexts or systems.

What are the optimal protocols for using GPC4 antibodies in Western blot analysis?

For optimal Western blot analysis using GPC4 antibodies, follow these methodological guidelines:

• Sample preparation:

  • Tissues with known GPC4 expression such as brain and kidney are recommended as positive controls

  • Use appropriate lysis buffers containing protease inhibitors to prevent degradation

  • For membrane-associated proteins like GPC4, ensure complete solubilization using detergent-containing buffers

• Gel electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation of GPC4 (observed molecular weight: 62 kDa)

  • Ensure complete transfer to PVDF or nitrocellulose membranes (PVDF often preferred for glycoproteins)

• Blocking and antibody incubation:

  • Block with 5% non-fat milk or BSA in TBST for 1-2 hours at room temperature

  • For primary antibody incubation with 13048-1-AP, use dilutions between 1:2000-1:10000

  • Incubate at 4°C overnight for optimal sensitivity

  • Wash thoroughly with TBST (at least 3-5 washes, 5 minutes each)

  • Use appropriate HRP-conjugated secondary antibodies (typically anti-rabbit IgG for most GPC4 antibodies)

• Detection and analysis:

  • Use ECL detection systems appropriate for your expected signal intensity

  • The expected band for GPC4 should appear at approximately 62 kDa

  • Be aware that post-translational modifications, particularly glycosylation, may result in band shifting or multiple bands

• Controls and validation:

  • Include positive control tissues (brain, kidney) and negative controls

  • Consider using GPC4 knockdown/knockout samples for antibody validation where available (published KD/KO applications exist for some antibodies)

Since GPC4 can undergo extensive post-translational modifications, particularly glycosylation and the addition of heparan sulfate chains, researchers should be prepared to observe some variability in the apparent molecular weight across different tissue and cell types.

What are the best practices for immunohistochemical detection of GPC4?

For optimal immunohistochemical (IHC) detection of GPC4 in tissue samples, follow these methodological guidelines:

• Tissue preparation and antigen retrieval:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissues, which have been validated for multiple GPC4 antibodies

  • Perform antigen retrieval using TE buffer pH 9.0 (recommended for 13048-1-AP) or alternatively citrate buffer pH 6.0

  • Proper antigen retrieval is critical for unmasking GPC4 epitopes that may be masked during fixation

• Antibody selection and dilution:

  • For 13048-1-AP, use dilutions between 1:500-1:2000

  • For ab246973, a 1:20 dilution has been validated

  • For TA316798, use at 15-20 μg/ml

  • Titrate the antibody concentration for your specific tissue type and fixation conditions

• Staining protocol:

  • Block endogenous peroxidase activity with hydrogen peroxide

  • Use appropriate blocking solution to minimize background staining

  • Incubate with primary antibody at 4°C overnight or at room temperature for 1-2 hours

  • Use detection systems compatible with the primary antibody host species (typically anti-rabbit detection systems)

  • Counterstain nuclei with hematoxylin for proper tissue orientation

• Tissue selection and controls:

  • Positive control tissues include:

    • Human stomach (validated for 13048-1-AP)

    • Human liver, kidney, and pancreas (validated for ab246973)

  • Include negative control tissues (e.g., human tonsil has shown no reactivity with ab246973)

  • Use isotype controls to assess non-specific binding

• Interpretation and analysis:

  • GPC4 is primarily a cell surface and extracellular matrix protein

  • Evaluate staining pattern, intensity, and subcellular localization

  • Compare staining patterns with published literature and database resources

For multiplexed staining approaches, careful antibody selection is necessary to ensure compatibility of primary antibody host species and detection systems.

How can I use GPC4 antibodies to investigate its role in developmental processes?

GPC4 plays significant roles in developmental processes, particularly in kidney tubule formation and central nervous system development . To investigate these developmental roles using GPC4 antibodies, consider these advanced approaches:

• Temporal expression analysis:

  • Use GPC4 antibodies on tissue sections or whole embryos at different developmental stages

  • Compare GPC4 expression patterns with developmental markers to correlate expression with specific developmental events

  • Combine with lineage tracing approaches to track GPC4-expressing cells throughout development

• Co-localization studies:

  • Perform double or triple immunofluorescence staining using GPC4 antibodies (e.g., 13048-1-AP at 1:200-1:800 dilution or ab246973 at 4μg/ml) alongside antibodies against:

    • Developmental signaling pathway components (Wnt, Hedgehog, FGF)

    • Cell type-specific markers to identify GPC4-expressing cell populations

    • Extracellular matrix components to understand GPC4's position in tissue architecture

• Functional perturbation experiments:

  • Compare GPC4 expression patterns in normal versus perturbed developmental systems

  • Use GPC4 antibodies to validate knockdown/knockout efficiency in functional studies

  • Implement rescue experiments with recombinant GPC4 followed by antibody detection to confirm specificity

• Ex vivo and organoid systems:

  • Apply GPC4 antibodies in developing organoid systems (kidney, brain) to track expression

  • Use flow cytometry with GPC4 antibodies to isolate specific progenitor populations

  • Combine with live imaging techniques to correlate GPC4 expression with cellular behaviors

• Cross-species comparative approaches:

  • Leverage antibodies with cross-species reactivity (e.g., 13048-1-AP reacts with human, mouse, rat; CAB12805 with human and mouse) to compare GPC4 expression patterns across evolutionary distances

  • Use this information to identify conserved versus divergent aspects of GPC4 function

When interpreting developmental studies with GPC4 antibodies, consider that both the protein expression and its post-translational modifications (particularly heparan sulfate chains) may change during development, potentially affecting epitope accessibility and antibody binding.

What approaches can be used to study GPC4's interactions with signaling pathways?

GPC4, as a cell surface proteoglycan, interacts with various growth factors and signaling molecules, influencing processes such as cell proliferation, migration, and differentiation . To investigate these interactions, researchers can employ several sophisticated approaches:

• Co-immunoprecipitation (Co-IP) studies:

  • Use GPC4 antibodies to immunoprecipitate GPC4 along with its binding partners

  • Recommended antibodies include those with validated IP applications

  • Analyze co-precipitated proteins by mass spectrometry or Western blotting for known interacting partners

  • Consider using crosslinking approaches to capture transient interactions

• Proximity ligation assays (PLA):

  • Combine GPC4 antibodies with antibodies against suspected interaction partners

  • This technique allows visualization of protein-protein interactions within 40 nm distance

  • Particularly useful for detecting interactions in situ in tissue sections or cultured cells

  • Requires careful selection of primary antibodies from different host species

• Immunofluorescence co-localization:

  • Use GPC4 antibodies (e.g., 13048-1-AP at 1:200-1:800 or ab246973 at 4μg/ml) alongside antibodies for signaling pathway components

  • Perform high-resolution confocal or super-resolution microscopy

  • Quantify co-localization using appropriate software and statistical measures

  • Combine with pathway activation markers to correlate GPC4 presence with signaling activity

• Flow cytometry for signaling studies:

  • Use recombinant antibodies from IPI optimized for flow cytometry

  • Combine with intracellular signaling antibodies to correlate GPC4 surface expression with pathway activation

  • Sort GPC4-high versus GPC4-low populations for downstream signaling analysis

• Functional interaction studies:

  • Compare signaling pathway activity in wild-type versus GPC4-deficient systems

  • Use GPC4 antibodies to validate and track expression in these models

  • Combine with pathway inhibitors to determine epistatic relationships

When designing these experiments, researchers should account for potential limitations in antibody access to GPC4 epitopes due to interactions with signaling molecules or structural conformations that may occur in specific signaling contexts.

How can GPC4 antibodies be used in cancer research applications?

GPC4 dysregulation has been implicated in cancer development and progression . Researchers can leverage GPC4 antibodies for various cancer research applications:

• Expression profiling across cancer types and stages:

  • Use immunohistochemistry with GPC4 antibodies (e.g., 13048-1-AP at 1:500-1:2000, ab246973 at 1:20, or TA316798 at 15-20 μg/ml) on tumor tissue microarrays

  • Compare expression between tumor and matched normal tissues

  • Correlate expression with clinical parameters including stage, grade, and patient outcomes

  • Develop scoring systems for GPC4 expression intensity and distribution

• Cellular localization in tumor microenvironments:

  • Perform multiplex immunofluorescence combining GPC4 antibodies with:

    • Cancer cell markers

    • Stromal cell markers

    • Immune cell markers

  • Analyze whether GPC4 is expressed by tumor cells, stromal cells, or both

  • Map spatial relationships between GPC4-expressing cells and other components of the tumor microenvironment

• Functional studies in cancer models:

  • Use Western blotting with GPC4 antibodies (e.g., 13048-1-AP at 1:2000-1:10000) to validate knockdown/knockout efficiency in cancer cell lines

  • Track GPC4 expression changes in response to therapeutic interventions

  • Monitor GPC4 expression in drug-resistant versus sensitive cell populations

• Biomarker development:

  • Assess whether GPC4 expression correlates with response to specific therapies

  • Develop standardized protocols for GPC4 immunohistochemistry that could be translated to clinical applications

  • Combine with other biomarkers to improve predictive or prognostic value

• Therapeutic targeting validation:

  • Use GPC4 antibodies to confirm target engagement in therapeutic development

  • Monitor changes in GPC4 expression or localization in response to targeted therapies

  • Validate specificity of therapeutic antibodies against GPC4 in comparison to research antibodies

For cancer research applications, researchers should be aware that GPC4 expression patterns and post-translational modifications may differ significantly between cancer types and even within heterogeneous tumors, necessitating careful validation in each specific cancer context.

What are common challenges when working with GPC4 antibodies and how can they be addressed?

Researchers often encounter several challenges when working with GPC4 antibodies. Here are common issues and their solutions:

• Background staining in immunohistochemistry/immunofluorescence:

  • Problem: High background or non-specific staining

  • Solutions:

    • Optimize blocking conditions (try 5-10% serum from the species of secondary antibody)

    • Increase washing steps duration and frequency

    • Titrate primary antibody to optimal concentration (may need more dilute than recommended)

    • For 13048-1-AP, try dilutions at the higher end of the recommended range (closer to 1:2000 for IHC)

    • Consider antigen retrieval optimization (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

• Multiple bands in Western blot:

  • Problem: Detecting bands at unexpected molecular weights

  • Solutions:

    • GPC4 is subject to post-translational modifications, especially glycosylation

    • The expected molecular weight is 62 kDa, but modifications may alter migration

    • Include positive control tissues (brain, kidney) to establish valid band pattern

    • Consider enzymatic deglycosylation to confirm specific bands

    • Use GPC4 knockdown/knockout samples as negative controls

• Weak or absent signal:

  • Problem: No detection despite expected GPC4 expression

  • Solutions:

    • For WB, try lower dilutions of primary antibody (e.g., 1:2000 instead of 1:10000)

    • For IHC/IF, ensure proper antigen retrieval (critical for FFPE samples)

    • Extend primary antibody incubation time (overnight at 4°C)

    • Use more sensitive detection systems (e.g., polymer-based for IHC, high-sensitivity ECL for WB)

    • Confirm sample integrity and proper storage conditions

• Inconsistent results between experiments:

  • Problem: Variable staining or detection across experiments

  • Solutions:

    • Standardize protocols, including fixation times, buffer compositions, and incubation conditions

    • Consider using recombinant antibodies which offer greater batch-to-batch consistency

    • Include consistent positive controls in every experiment

    • Prepare larger aliquots of antibody to minimize freeze-thaw cycles

    • Follow recommended storage conditions (e.g., -20°C with 50% glycerol for 13048-1-AP)

• Cross-reactivity concerns:

  • Problem: Potential detection of related glypican family members

  • Solutions:

    • Review specificity data (e.g., TA316798 shows no homology with other human proteins except PKD2L1 (44%))

    • Validate results with a second GPC4 antibody targeting a different epitope

    • Include controlled experiments with cells/tissues known to express other glypicans but not GPC4

Implementation of these troubleshooting strategies should significantly improve results when working with GPC4 antibodies across different experimental applications.

How can I validate the specificity of my GPC4 antibody?

Validating antibody specificity is crucial for ensuring reliable research results. For GPC4 antibodies, consider implementing these validation approaches:

• Genetic validation:

  • Knockdown/knockout controls: Use siRNA, shRNA, or CRISPR-Cas9 to reduce or eliminate GPC4 expression

  • Several GPC4 antibodies (including 13048-1-AP) have published KD/KO applications that can serve as reference protocols

  • Compare staining/signal between wild-type and KD/KO samples using the same antibody and protocol

  • This approach represents the gold standard for antibody validation

• Peptide competition assays:

  • Pre-incubate the antibody with excess immunizing peptide (when available)

  • For antibodies raised against synthetic peptides (like TA316798, which uses a 16 amino acid peptide from C-terminus)

  • Specific signals should be blocked or significantly reduced

  • Non-specific binding will typically remain unchanged

• Multiple antibody validation:

  • Use two or more antibodies targeting different epitopes of GPC4

  • Compare staining patterns across antibodies (e.g., ab246973 targeting aa 450-550 versus TA316798 targeting C-terminus)

  • Consistent patterns across antibodies increase confidence in specificity

  • Divergent results warrant further investigation

• Orthogonal validation:

  • Compare protein detection results with mRNA expression data (RT-PCR, RNA-seq, or in situ hybridization)

  • While not a direct validation of antibody specificity, concordance between protein and mRNA expression patterns increases confidence

  • Consider publicly available transcriptome datasets to guide tissue selection

• Cross-reactivity testing:

  • Test antibody against recombinant proteins of all glypican family members

  • Recombinant antibodies from IPI undergo cross-reactivity analysis of all target family members via flow cytometry

  • Verify specificity against GPC4 versus other glypicans (GPC1-3, GPC5-6)

  • Particularly important when studying tissues expressing multiple glypican family members

• Mass spectrometry correlation:

  • For advanced validation, immunoprecipitate GPC4 using the antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm the presence of GPC4 peptides in the immunoprecipitated material

  • This approach can also identify potential cross-reacting proteins

By employing multiple validation strategies, researchers can establish high confidence in the specificity of their GPC4 antibody and the reliability of their experimental results.

How should I interpret conflicting results between different GPC4 antibodies?

When faced with conflicting results between different GPC4 antibodies, systematic analysis is required to determine the most reliable data. Consider this methodological approach:

• Epitope mapping analysis:

  • Review the epitopes targeted by each antibody:

    • ab246973 targets amino acids 450-550 of human GPC4

    • TA316798 targets a 16 amino acid peptide from the C-terminus

  • Differences in accessibility of these epitopes could explain discrepancies

  • Post-translational modifications or protein interactions may mask specific epitopes

  • Membrane-associated proteins like GPC4 may have different epitope accessibility depending on fixation or extraction methods

• Antibody format and validation comparison:

  • Compare the validation data for each antibody:

    • Published literature citations (e.g., 13048-1-AP has been cited in multiple publications)

    • Manufacturer validation data (images, controls, protocols)

    • Recombinant antibodies (like those from IPI) often undergo more extensive validation

  • Antibodies with more extensive validation generally warrant higher confidence

• Experimental context analysis:

  • Evaluate each antibody's performance in specific applications:

    • Some antibodies may perform better in WB than IHC or vice versa

    • 13048-1-AP is validated for multiple applications (WB, IHC, IF/ICC, ELISA)

    • ab246973 is specifically validated for IHC-P and ICC/IF

  • Fixation methods, buffer compositions, and protein conformation may affect epitope recognition differently across applications

• Biological context consideration:

  • GPC4 undergoes extensive post-translational modifications:

    • Glycosylation patterns may differ between tissues/cell types

    • Heparan sulfate attachment can affect antibody accessibility

    • Proteolytic processing may generate fragments recognized by some antibodies but not others

  • Different developmental stages or disease states may alter GPC4 structure or processing

• Systematic validation approach:

  • Implement genetic controls (KD/KO) with each antibody

  • Perform side-by-side comparisons under identical conditions

  • Include positive and negative control tissues for each antibody

  • Consider orthogonal methods (mRNA analysis, mass spectrometry) to resolve conflicts

• Result integration strategy:

  • Prioritize results confirmed by multiple antibodies

  • Give more weight to results validated by genetic approaches

  • Consider results from recombinant antibodies with defined specificity profiles

  • Acknowledge limitations and conflicts in research publications

When reporting conflicting results, researchers should transparently document the discrepancies, the conditions under which each antibody was used, and provide a reasoned interpretation of which results are likely most reliable based on the validation evidence.

What emerging applications exist for GPC4 antibodies in therapeutic development?

GPC4 antibodies are increasingly being explored for therapeutic applications beyond their traditional research uses. Several emerging applications include:

• Targeted cancer therapies:

  • GPC4 dysregulation has been implicated in several cancers

  • Therapeutic antibodies targeting GPC4 could:

    • Deliver cytotoxic payloads specifically to GPC4-overexpressing cancer cells

    • Block interactions between GPC4 and growth factors to inhibit tumor growth

    • Recruit immune cells to attack GPC4-positive cancer cells (antibody-dependent cellular cytotoxicity)

  • Research-grade antibodies can help identify cancer types with high GPC4 expression as potential therapeutic targets

• Developmental disorder interventions:

  • Given GPC4's role in kidney tubule and central nervous system development

  • Therapeutic approaches might:

    • Modulate GPC4 signaling to correct developmental abnormalities

    • Use GPC4 antibodies as biomarkers to monitor developmental processes

    • Target downstream effectors of GPC4 signaling identified through research antibody studies

• Biomarker development:

  • GPC4 expression patterns may serve as diagnostic or prognostic indicators

  • Research with current antibodies can establish:

    • Threshold expression levels associated with disease states

    • Correlation between GPC4 expression and treatment response

    • Changes in GPC4 glycosylation patterns in disease contexts

• Regenerative medicine applications:

  • Manipulating GPC4 signaling might enhance tissue regeneration

  • Research antibodies can help:

    • Track GPC4 expression during healing and regeneration

    • Identify cell populations with regenerative potential based on GPC4 expression

    • Monitor the effects of GPC4 modulation on tissue repair processes

• Antibody engineering approaches:

  • Current research antibodies provide valuable starting points for:

    • Developing bispecific antibodies targeting GPC4 and other molecules

    • Creating antibody fragments with enhanced tissue penetration

    • Engineering antibodies with modified Fc regions for specific effector functions

While most current GPC4 antibodies are designed for research applications, the knowledge generated through their use is laying the groundwork for therapeutic development. The extensive characterization of these research antibodies, particularly the recombinant antibodies with well-defined specificity profiles , provides essential information for future therapeutic antibody design.

How can advanced imaging techniques enhance GPC4 antibody applications?

Advanced imaging technologies are revolutionizing the applications of GPC4 antibodies in research, enabling more detailed analysis of its expression, localization, and function:

• Super-resolution microscopy:

  • Techniques such as STORM, PALM, and STED overcome the diffraction limit

  • Applications with GPC4 antibodies include:

    • Nanoscale localization of GPC4 within membrane microdomains

    • Precise mapping of GPC4 distribution relative to signaling partners

    • Visualization of GPC4 clustering dynamics during signaling events

  • Antibodies like 13048-1-AP (1:200-1:800) or ab246973 (4μg/ml) can be adapted for these approaches

• Live-cell imaging techniques:

  • Using non-permeabilizing GPC4 antibody labeling for live cells:

    • Track GPC4 dynamics during developmental processes

    • Monitor internalization and trafficking of GPC4 upon ligand binding

    • Observe real-time changes in GPC4 distribution during cell migration

  • May require development of specialized non-disruptive antibody formats or fragments

• Intravital imaging:

  • Application of GPC4 antibodies in whole animal imaging:

    • Track GPC4-expressing cells in developmental contexts

    • Monitor tumor cells expressing GPC4 during metastasis

    • Visualize GPC4-mediated processes in intact tissues

  • Requires optimization of antibody delivery and signal detection in deep tissues

• Correlative light and electron microscopy (CLEM):

  • Combining immunofluorescence with electron microscopy:

    • Ultrastructural localization of GPC4 at the cell surface

    • Detailed analysis of GPC4 distribution in specialized membrane domains

    • Visualization of GPC4 in relation to extracellular matrix components

  • May require specialized fixation and embedding protocols to preserve epitopes

• Multiplexed imaging approaches:

  • Cyclic immunofluorescence or mass cytometry imaging:

    • Simultaneous visualization of GPC4 with dozens of other markers

    • Comprehensive mapping of GPC4 in complex tissues

    • Identification of cell types expressing GPC4 in heterogeneous samples

  • Compatible with existing GPC4 antibodies when properly optimized

• Expansion microscopy:

  • Physical expansion of specimens for enhanced resolution:

    • Improved visualization of GPC4 distribution in dense tissues

    • Better separation of membrane-associated GPC4 from intracellular pools

    • Enhanced detection of low-abundance GPC4 expression

  • Requires validation that antibody epitopes remain accessible after expansion

These advanced imaging approaches, when combined with well-validated GPC4 antibodies, promise to provide unprecedented insights into GPC4 biology, potentially revealing new functions and interactions that have been previously undetectable with conventional imaging techniques.